Physician profile
Marc E Goldschmidt
NPI 1932109493
$148,034.95
in general payments reported to CMS, 2019-2025
36 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $20K · 2021: $17K · 2022: $12K · 2023: $29K · 2024: $29K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $9,250 · Food and Beverage: $7,088 · Honoraria: $3,900 · Travel and Lodging: $2,098 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,546.00 |
| Consulting Fee | $9,250.00 |
| Food and Beverage | $7,087.51 |
| Honoraria | $3,900.00 |
| Travel and Lodging | $2,098.01 |
| Education | $128.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40,584.03 | 2019-2025 | Camzyos, Opdivo, Eliquis |
| Pfizer INC. | $35,271.55 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $22,270.64 | 2023-2024 | Verquvo, Steglatro |
| Astrazeneca Pharmaceuticals Lp | $16,926.83 | 2019-2024 | Lokelma |
| Abbott Laboratories | $11,350.94 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Impulse Dynamics (USA) INC. | $8,431.72 | 2021-2025 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $3,836.08 | 2019-2025 | |
| Bridgebio Pharma, INC. | $2,914.90 | 2025 | Attruby |
| Abiomed | $2,059.16 | 2019-2025 | Impella |
| Medtronic Vascular, INC. | $1,404.67 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $529.85 | 2019-2023 | Opsumit, Uptravi |
| Celgene Corporation | $300.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.75 | 2019-2024 | Jardiance |
| Amgen INC. | $214.98 | 2019-2022 | |
| Akcea Therapeutics, INC. | $213.38 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endotronix, INC. | $211.23 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Boston Scientific Corporation | $131.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $124.96 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.22 | 2019-2023 | |
| Vifor Pharma, INC. | $119.52 | 2019-2021 | |
| United Therapeutics Corporation | $107.79 | 2019-2024 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.43 | 2020-2021 | |
| Amarin Pharma, INC. | $87.72 | 2019-2020 | |
| Bardy Diagnostics, INC. | $57.34 | 2020-2022 | |
| Gilead Sciences, INC. | $49.12 | 2019 | |
| Daiichi Sankyo INC. | $44.71 | 2024 | Injectafer |
| Edwards Lifesciences Corporation | $43.21 | 2019 | |
| Scpharmaceuticals INC. | $34.49 | 2023 | |
| Kiniksa Pharmaceuticals, Ltd. | $32.04 | 2023 | Arcalyst |
| Nuwellis, INC. | $30.39 | 2019 | |
| Chiesi USA, INC. | $29.89 | 2025 | Cleviprex, Kengreal |
| Sanofi-Aventis U.S. LLC | $26.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.13 | 2019 | |
| Medtronic, INC. | $24.29 | 2021 | |
| Smith+Nephew, INC. | $18.21 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Goldschmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.